NCT04417621 2026-03-12
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Novartis
Phase 2 Active not recruiting
Clinical Trials
41 trialsNCT02712723 2026-03-11
FELINE
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT07405801 2026-03-09
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT05843253 2026-03-04
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
NCT05467891 2026-02-27
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT02934568 2026-02-12
Ribociclib (LEE011) Rollover Study for Continued Access
Novartis
Phase 2 Active not recruiting
NCT03008408 2026-02-11
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT06849947 2025-12-24
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
Samsung Medical Center
Phase 2 Not yet recruiting
NCT03673124 2025-12-23
Ribociclib and Letrozole Treatment in Ovarian Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT06409390 2025-12-04
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04116541 2025-11-21
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT06062498 2025-10-20
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Phase 2 Recruiting
NCT03283384 2025-09-19
NEOLBC
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT05900206 2025-09-02
ARIADNE
Karolinska University Hospital
Phase 2 Recruiting
NCT05625087 2025-08-20
SAFIR 03
UNICANCER
Phase 2 Active not recruiting
NCT06953882 2025-07-14
SELECT
Yale University
Phase 2 Recruiting
NCT03114527 2025-04-04
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT05296746 2025-03-18
RIBOLARIS
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT05816655 2025-03-18
Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Korea University Guro Hospital
Phase 2 Recruiting
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02632045 2024-12-06
MAINTAIN
Columbia University
Phase 2 Completed
NCT03070301 2024-10-10
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT05163106 2024-08-02
NEOLETRIB
University Hospital, Akershus
Phase 2 Completed
NCT06481956 2024-07-01
T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
Zhejiang Cancer Hospital
Phase 2 Enrolling by invitation
NCT03484923 2024-06-18
PLATforM
Novartis
Phase 2 Completed
NCT02035813 2024-06-04
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
University of Ulm
Phase 2 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT03477396 2024-02-20
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT03555877 2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2 Completed
NCT05766410 2023-03-16
ORACLE-RIPA
National Taiwan University Hospital
Phase 2 Recruiting
NCT03078751 2021-10-11
EarLEE-1
Novartis
Phase 2 Completed
NCT03248427 2021-03-17
CORALLEEN
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT02420691 2020-10-30
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02300987 2020-10-26
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Novartis
Phase 2 Completed
NCT02187783 2019-07-18
SIGNATURE
Novartis
Phase 2 Completed
NCT02571829 2016-11-23
A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
Hadassah Medical Organization
Phase 2 Unknown
NCT01919229 2016-01-01
MONALEESA-1
Novartis
Phase 2 Terminated